Singapore markets closed

Straits Times Index
3,331.70
+5.42(+0.16%)
S&P 500
5,463.95
-5.35(-0.10%)
Dow
38,990.43
-121.73(-0.31%)
Nasdaq
17,770.91
+53.26(+0.30%)
Bitcoin USD
61,656.50
-251.62(-0.41%)
CMC Crypto 200
1,279.20
-4.58(-0.36%)

ITCI Aug 2024 80.000 call

OPR - OPR Delayed price. Currency in USD

Add to watchlist

1.7500

-1.0000

(-36.36%)

As of 02:07PM EDT. Market open.

Zacks
Intra-Cellular's (ITCI) Caplyta Boosts Sales, Dependence a Woe
Intra-Cellular (ITCI) is witnessing strong Caplyta sales, driven by an increasing prescription rate. However, the company is heavily dependent on Caplyta sales for growth, which is a concern.
Zacks
Biotech Stock Roundup: ITCI Up on Study Data, ZNTL, OVID Down on Updates & More News
Intra-Cellular Therapies (ITCI) and Zentalis Pharmaceuticals, Inc. (ZNTL) are in the spotlight following pipeline and regulatory updates, respectively.
Zacks
Intra-Cellular (ITCI) Up as Second Depression Study Meets Goals
Intra-Cellular (ITCI) gains 10% after achieving key goals in the second late-stage study evaluating lumateperone 42 mg as an adjunctive therapy to antidepressants for the treatment of MDD.